Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

General Anesthesia Drugs Market – Insights

General anesthesia is a condition of unconsciousness induced using general anesthetic agents drugs. The primary objective of general anesthesia is to induce unconsciousness, analgesia, and loss of reflexes of the autonomic nervous system (ANS). General anesthesia administered through intravenous route is categorized as IV anesthetics and is used for induction and for short surgery to relieve anxiety and induce amnesia. IV drugs are widely used in cardiovascular disease (CVD) and chronic renal disease (CRD) surgeries.

The global general anesthesia drugs market is estimated to account for US$ 5999.7 Mn in terms of value by the end of 2027.

Global General Anesthesia Drugs Market: Drivers

Increasing prevalence of CVD is expected to boost growth of the global general anesthesia drugs market over the forecast period. For instance, according to American Heart Association’s Heart Disease and Stroke Statistics 2018, around 92.1 million adults in the U.S. are suffering from some form of CVD or the after-effects of stroke.

Ageing population is at high risk of suffering from chronic diseases such as CRD, CVD and diabetes, which leads to increasing demand for surgical interventions. Therefore, increasing geriatric population is also expected to boost growth of the market. For instance, according to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015.

Asia Pacific region held dominant position in the global general anesthesia drugs market in 2018, accounting for 30.4% share in terms of volume, followed by North America.

Figure 1. Global General Anesthesia Drugs Market Value (US$ Mn), by Region, 2018

General Anesthesia Drugs  | Coherent Market Insights

Global General Anesthesia Drugs Market: Restraints

Use of general anesthesia drugs may lead to vomiting, nausea, irregularity in heart rhythm, body temperature, blood pressure, and respiratory rate, sore throat and irritation in the respiratory system, which is expected to hinder growth of the global general anesthesia drugs market.

Moreover, general anesthetic drugs can lead to complications such as allergic reactions. Moreover, the drugs may also be ineffective in some cases. Some fatal complications include allergic reactions, cardiovascular collapse, drug interactions, prolonged apnea, respiratory depression, jaundice, and anesthesia awareness. Such scenario is also expected to hamper the market growth.

Global General Anesthesia Drugs Market: Opportunities

Increasing funding to expand care for patients with disabilities is expected to offer lucrative growth opportunities for market players. For instance, in December 2019, The Rutgers School of Dental Medicine announced that it is expected to receive a US$ 250,000 funding for extra staffing and additional surgical resources for the treatment of special care patients who need general anesthesia.

Moreover, increasing R&D in general anesthesia is also expected to propel growth of the market. For instance, in April 2019, researchers from Duke University Medical Center reported that diverse drugs that induce general anesthesia activate a brain circuit that brings on sleep.

General Anesthesia Drugs  | Coherent Market Insights

Propofol segment in the global general anesthesia drugs market was valued at US$ 1,300.6 Mn in 2018 and is expected to reach US$ 1,916.2 Mn by 2027 at a CAGR of 5.7% during the forecast period.

Market Trends/Key Takeaways

The market is witnessing increasing adoption of alternatives to general anesthesia. For instance, in November 2019, The U.S. Food and Drug Administration approved Tubes Under Local Anesthesia (Tula) System for the delivery of tympanostomy tubes. The approval offers patients an option for the treatment of recurrent ear infections that does not require general anesthesia.

Increasing preference for minimally invasive alternative to open-heart surgery is expected to decrease adoption of general anesthesia drugs. For instance, in December 2019, HCA Houston Healthcare Kingwood successfully completed a minimally invasive alternative to open-heart surgery using transcatheter aortic valve replacement procedures.

Global General Anesthesia Drugs Market: Competitive Landscape

Major players operating in the global general anesthesia drugs market include, Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, and Hospira Inc.

Global General Anesthesia Drugs Market: Key Developments

Key players in the market are focused on raising funds to expand their product portfolio. For instance, in June 2019, PAION AG, a Germany-based pharmaceutical company specialized in anesthesia and sedation drugs announced that it will receive a funding of around US$ 20 million from The European Investment Bank.

Key players in the market are focused on adopting partnership strategies to expand their product portfolio. For instance, in June 2019, SunGen Pharma partnered with Athenex Pharmaceuticals for launching Bivalirudin for Injection in the near future.

General anesthesia is a therapeutically induced condition of unconsciousness; that is, loss of protective reflexes, which results from the use of one or multiple general anesthetic agents. The drug is administered to allow performing the medical procedures which are unbearably painful for the patient. A range of medicines can be administered, the overall aim of which is to ensure unconsciousness, analgesia, and loss of reflexes of the ANS or autonomic nervous system. In some cases, general anesthetic drugs are used for paralyzing the skeletal muscles.

Key features of the study:

  • This report provides in-depth analysis of the General Anesthesia Drugs market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global General Anesthesia Drugs market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, and Hospira Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global General Anesthesia Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global General Anesthesia Drugs market

Detailed Segmentation:

  • General Anesthesia Drugs Market, By Molecule Type:
    • Propofol
    • Sevoflurane
    • Dexmedetomidine
    • Desflurane
    • Remifentanil
    • Midazolam
    • Others
  • General Anesthesia Drugs Market, By Region:
    • North America
      • By Molecule Type:
        • Propofol
        • Sevoflurane
        • Dexmedetomidine
        • Desflurane
        • Remifentanil
        • Midazolam
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Molecule Type:
        • Propofol
        • Sevoflurane
        • Dexmedetomidine
        • Desflurane
        • Remifentanil
        • Midazolam
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Molecule Type:
        • Propofol
        • Sevoflurane
        • Dexmedetomidine
        • Desflurane
        • Remifentanil
        • Midazolam
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Molecule Type:
        • Propofol
        • Sevoflurane
        • Dexmedetomidine
        • Desflurane
        • Remifentanil
        • Midazolam
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Molecule Type:
        • Propofol
        • Sevoflurane
        • Dexmedetomidine
        • Desflurane
        • Remifentanil
        • Midazolam
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Molecule Type:
        • Propofol
        • Sevoflurane
        • Dexmedetomidine
        • Desflurane
        • Remifentanil
        • Midazolam
        • Others
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Baxter International Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • AstraZeneca
    • AbbVie Inc.
    • B. Braun Melsungen AG
    • Fresenius SE & Co. KGaA
    • Hospira Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Molecule Type
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • Regulatory Scenario
    • PEST Analysis
    • Mergers and Acquisitions
  4. Global General Anesthesia Drugs Market, By Molecule Type, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Propofol
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Keratolytics
        • Moisturizers
        • Retinoids
        • SunScreens
        • Hair Removals
    • Sevoflurane
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Dexmedetomidine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Desflurane
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Remifentanil
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Midazolam
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Global General Anesthesia Drugs Market, By Region, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  6. Competitive Landscape
    • Company Profiles
      • Baxter International Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AstraZeneca
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • B. Braun Melsungen AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Fresenius SE & Co. KGaA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hospira Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 36 market data tables and 34 figures on “General Anesthesia Drugs Market - Global forecast to 2027”.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner